Bone density and shape as determinants of bone strength in IGF-I and/or pamidronate-treated ovariectomized rats
Bone density and shape as determinants of bone strength in IGF-I and/or pamidronate-treated ovariectomized rats
复制标题
DOI：
10.1007/bf01622738
复制
发表时间：
1996-01-01
影响因子：
4
通讯作者：
Bonjour, JP
中科院分区：
文献类型：
--
作者：
Ammann, P;Rizzoli, R;Bonjour, JP
区域骨矿物质密度（BMD）是骨强度和骨折风险的主要决定因素。其他因素包括骨小梁微结构和骨尺寸也有助于骨强度。为了探讨骨密度和骨尺寸的骨强度的相对重要性，强度和后者变量之间的关系进行了评估，在不同的实验条件下，在卵巢切除大鼠。采用双能X线骨密度仪测量骨密度，评价压缩和弯曲状态下的骨强度。干预措施的目的是增加骨小梁骨密度与雌激素缺乏诱导的骨丢失（OVX）的治疗与帕米膦酸盐，骨吸收抑制剂，或修改骨尺寸，特别是直径，通过管理的生长因子IGF-I。在OVX大鼠中，帕米膦酸盐治疗增加了腰椎和股骨颈水平的BMD，并相应增加了骨强度（r = 0.789，p
Areal bone mineral density (BMD) is a major determinant of bone strength and thereby of fracture risk. Other factors including trabecular microarchitecture and bone dimensions also contribute to bone strength. To investigate the relative importance for bone strength of BMD and bone dimensions, the relations between strength and the latter variables were evaluated under different experimental conditions in ovariectomized rats. Bone strength was assessed in compression and bending with measurement of BMD by dual-energy X-ray absorptiometry. Interventions were designed to increase trabecular BMD in rats with estrogen deficiency-induced bone loss (OVX) by treatment with pamidronate, an inhibitor of bone resorption, or to modify bone dimensions, particularly diameter, by administration of the growth factor IGF-I. In OVX rats, pamidronate treatment increased BMD with a commensurate increase in bone strength at the level of lumbar vertebrae and femoral neck (r = 0.789, p